Elamipretide (SS-31) Simply Explained

1. What It Is About

Elamipretide is a synthetically produced substance. It belongs to the class of peptides, which are short chains of amino acids. The compound is also referred to as SS-31. It has been investigated in studies since 2009. Elamipretide is designed to act within the powerhouses of cells, the mitochondria. There, it binds to a specific lipid in the inner membrane of mitochondria. This lipid is called cardiolipin and is essential for cellular energy production. Elamipretide is thought to protect the mitochondrial membrane, thereby stabilising the cell’s energy supply. There are no natural sources; the substance is manufactured in the laboratory. In studies, it is administered as an injection under the skin or into a vein. Oral tablets are not available. Elamipretide is primarily being investigated for fatigue, cardiovascular diseases, and rare inherited mitochondrial disorders.

2. What Studies Show

The clearest evidence to date comes from a rare inherited disorder called Barth syndrome. In this condition, mitochondrial lipid metabolism is impaired. In a study of 12 patients with Barth syndrome who received daily injections of elamipretide for 36 weeks, participants were able to walk an average of 95.9 metres further in six minutes than before treatment. Their quality of life and symptoms also improved measurably 1. In a further investigation involving 12 patients with Barth syndrome, blood lipid metabolism shifted in a more favourable direction after 12 weeks 3. Findings in another rare disorder, primary mitochondrial myopathy, were mixed. In a large study of 218 patients over 24 weeks, there was no improvement in walking distance, but patients reported less fatigue and improved quality of life 7. A smaller study of 36 patients with the same condition found a 64.5-metre increase in walking distance at the highest tested dose after five days, though this difference was not statistically significant 5. In heart failure, a single infusion in 24 patients reduced heart chamber size, but a 28-day treatment in 71 patients showed no sustained benefit 4 6. In a study of 39 healthy older adults, a single infusion improved energy production in muscle cells without changes in muscle strength or endurance 2. Across all studies, elamipretide was generally well tolerated, with injection-site reactions being the most common side effect.

3. What Remains Unclear

Many questions remain unanswered. Human studies to date have mostly been small and short in duration, involving between 12 and 218 participants and lasting from 4 to 168 weeks. Whether elamipretide remains safe with long-term use is unknown. It is also unclear whether antibodies against the compound may develop. The response appears to depend on the precise genetic cause of the disorder; some patients benefit while others do not, and the reasons for this variability are not understood. For heart failure and most other mitochondrial disorders, efficacy has not been established. Studies are lacking that assess whether treatment reduces hospitalisations or mortality. Moreover, most clinical trials have not included direct measurements of mitochondrial function in the body.

4. What This Means in Practice

Elamipretide is an investigational compound. For people with Barth syndrome, there is evidence suggesting improvements in physical performance and quality of life. For other mitochondrial disorders and heart failure, results are inconsistent. Individuals affected by these conditions should consult specialists with expertise in mitochondrial diseases. Current research is focused on identifying which patients might benefit most, requiring larger, genotype-stratified studies with longer follow-up. Until such data are available, the interpretation of elamipretide’s role remains provisional.

Full details with study numbers and sources: Detailed page on elamipretide (SS-31). For children: Elamipretide (SS-31) for children.